Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
R129220-25mg
|
25mg |
5
|
$9.90
|
|
|
R129220-100mg
|
100mg |
3
|
$19.90
|
|
|
R129220-200mg
|
200mg |
3
|
$29.90
|
|
|
R129220-1g
|
1g |
1
|
$49.90
|
|
|
R129220-5g
|
5g |
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
|
$99.90
|
|
|
R129220-25g
|
25g |
2
|
$319.90
|
|
Potent HMG-CoA reductase inhibitor
| Synonyms | Shufutan | Suvikan | Provisacor | ROSUVASTATIN CALCIUM (USP-RS) | ROSUVASTATIN CALCIUM [EP MONOGRAPH] | R0180 | EZALLOR | Rosuvastatin calcium | Rosuvastatin calcium- Bio-X | ZD 4522 Calcium |
|---|---|
| Specifications & Purity | Moligand™, ≥99% |
| Biochemical and Physiological Mechanisms | Potent HMG-CoA reductase inhibitor (IC50= 5.4 nM). Inhibits cholesterol synthesis in rat hepatocytesin vitroandin vivo. Reduces plasma LDL cholesterol levels. Enhances lentiviral transduction of natural killer cells. Orally bioavailable. |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Grade | Moligand™ |
| Action Type | INHIBITOR |
| Mechanism of action | HMG-CoA reductase inhibitor |
| Product Description |
Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM. |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Class | Diazines |
| Subclass | Pyrimidines and pyrimidine derivatives |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Phenylpyrimidines |
| Alternative Parents | Medium-chain hydroxy acids and derivatives Medium-chain fatty acids Beta hydroxy acids and derivatives Fluorobenzenes Halogenated fatty acids Heterocyclic fatty acids Hydroxy fatty acids Aryl fluorides Unsaturated fatty acids Organosulfonamides Organic sulfonamides Heteroaromatic compounds Aminosulfonyl compounds Secondary alcohols Carboxylic acid salts Monocarboxylic acids and derivatives Azacyclic compounds Carboxylic acids Organic calcium salts Organic metal halides Organic zwitterions Organofluorides Organonitrogen compounds Hydrocarbon derivatives Organopnictogen compounds Carbonyl compounds Organic oxides |
| Molecular Framework | Not available |
| Substituents | 4-phenylpyrimidine - 5-phenylpyrimidine - Medium-chain hydroxy acid - Medium-chain fatty acid - Beta-hydroxy acid - Fluorobenzene - Halobenzene - Halogenated fatty acid - Heterocyclic fatty acid - Hydroxy fatty acid - Fatty acid - Hydroxy acid - Benzenoid - Fatty acyl - Monocyclic benzene moiety - Aryl halide - Unsaturated fatty acid - Aryl fluoride - Organosulfonic acid amide - Organic sulfonic acid amide - Heteroaromatic compound - Aminosulfonyl compound - Organosulfonic acid or derivatives - Organic sulfonic acid or derivatives - Sulfonyl - Carboxylic acid salt - Secondary alcohol - Organic metal halide - Azacycle - Carboxylic acid derivative - Organic calcium salt - Carboxylic acid - Monocarboxylic acid or derivatives - Organooxygen compound - Organosulfur compound - Organic oxygen compound - Organopnictogen compound - Organic oxide - Organic salt - Hydrocarbon derivative - Carbonyl group - Alcohol - Organic nitrogen compound - Organic zwitterion - Organohalogen compound - Organofluoride - Organonitrogen compound - Aromatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions. |
| External Descriptors | organic calcium salt - N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine |
|
|
|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Pubchem Sid | 504763431 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504763431 |
| IUPAC Name | calcium;(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate |
| INCHI | InChI=1S/2C22H28FN3O6S.Ca/c2*1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32;/h2*5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30);/q;;+2/p-2/b2*10-9+;/t2*16-,17-;/m11./s1 |
| InChIKey | LALFOYNTGMUKGG-BGRFNVSISA-L |
| Smiles | CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C.CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C.[Ca+2] |
| Isomeric SMILES | CC(C1=NC(=NC(=C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C2=CC=C(C=C2)F)N(S(=O)(=O)C)C)C.CC(C1=NC(=NC(=C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C2=CC=C(C=C2)F)N(S(=O)(=O)C)C)C.[Ca+2] |
| PubChem CID | 5282455 |
| Molecular Weight | 500.57 |
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Feb 11, 2025 | R129220 | |
| Certificate of Analysis | Feb 11, 2025 | R129220 | |
| Certificate of Analysis | Feb 11, 2025 | R129220 | |
| Certificate of Analysis | Jan 10, 2025 | R129220 | |
| Certificate of Analysis | Jan 10, 2025 | R129220 | |
| Certificate of Analysis | Jul 10, 2024 | R129220 | |
| Certificate of Analysis | Apr 14, 2023 | R129220 | |
| Certificate of Analysis | Jan 25, 2023 | R129220 | |
| Certificate of Analysis | Oct 17, 2022 | R129220 | |
| Certificate of Analysis | Jul 27, 2022 | R129220 | |
| Certificate of Analysis | Jul 27, 2022 | R129220 | |
| Certificate of Analysis | Jul 27, 2022 | R129220 | |
| Certificate of Analysis | Jul 27, 2022 | R129220 | |
| Certificate of Analysis | Jul 27, 2022 | R129220 |
| Solubility | Solvent:DMSO, Max Conc. mg/mL: 50.06, Max Conc. mM: 100 |
|---|---|
| Sensitivity | heat sensitive |
| Specific Rotation[α] | -8° (C=1,CHCl3) |
| Melt Point(°C) | 160 °C |
| Molecular Weight | 1001.100 g/mol |
| XLogP3 | |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 20 |
| Rotatable Bond Count | 18 |
| Exact Mass | 1000.28 Da |
| Monoisotopic Mass | 1000.28 Da |
| Topological Polar Surface Area | 304.000 Ų |
| Heavy Atom Count | 67 |
| Formal Charge | 0 |
| Complexity | 761.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 2 |
| Covalently-Bonded Unit Count | 3 |
| 1. Jie Yang, Xiuhua Pan, Jun Zhang, Siyu Ma, Jianeng Zhou, Zengguang Jia, Yawen Wei, Zengyi Liu, Ning Yang, Qi Shen. (2022) Reprogramming dysfunctional dendritic cells by a versatile metabolism nano-intervenor for enhancing cancer combinatorial immunotherapy. Nano Today, 46 (101618). |
| 2. Jie Yang, Zengguang Jia, Jun Zhang, Xiuhua Pan, Yawen Wei, Siyu Ma, Ning Yang, Zengyi Liu, Qi Shen. (2022) Metabolic Intervention Nanoparticles for Triple-Negative Breast Cancer Therapy via Overcoming FSP1-Mediated Ferroptosis Resistance. Advanced Healthcare Materials, 11 (13): (2102799). |
| 3. Xie Qiu-shi, Zhang Jia-xin, Liu Ming, Liu Pei-hua, Wang Zhong-jian, Zhu Liang, Jiang Ling, Jin Meng-meng, Liu Xiao-nan, Liu Li, Liu Xiao-dong. (2020) Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine. ACTA PHARMACOLOGICA SINICA, 42 (3): (470-481). |
| 4. Kyeong-Ju Lee, Yoon-Mi Lee, Seong-Bin Yang, Jun-Hyuck Lee, Ha Rin Kim, Ji-Hong Lim, Jooho Park. (2024) A novel chemically engineered multifunctional statin conjugate as self-assembled nanoparticles inhibiting bile acid transporters. JOURNAL OF CONTROLLED RELEASE, 372 (885). |